CN117693340A - Nlrp3抑制剂治疗骨关节炎的给药方案 - Google Patents

Nlrp3抑制剂治疗骨关节炎的给药方案 Download PDF

Info

Publication number
CN117693340A
CN117693340A CN202280049591.4A CN202280049591A CN117693340A CN 117693340 A CN117693340 A CN 117693340A CN 202280049591 A CN202280049591 A CN 202280049591A CN 117693340 A CN117693340 A CN 117693340A
Authority
CN
China
Prior art keywords
nlrp3 inhibitor
nlrp3
compound
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280049591.4A
Other languages
English (en)
Chinese (zh)
Inventor
L·科尔曼
C·法拉第
E·加特利克
M·希克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN117693340A publication Critical patent/CN117693340A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280049591.4A 2021-07-23 2022-07-20 Nlrp3抑制剂治疗骨关节炎的给药方案 Pending CN117693340A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163224890P 2021-07-23 2021-07-23
US63/224,890 2021-07-23
PCT/IB2022/056695 WO2023002399A1 (en) 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
CN117693340A true CN117693340A (zh) 2024-03-12

Family

ID=82846336

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280049591.4A Pending CN117693340A (zh) 2021-07-23 2022-07-20 Nlrp3抑制剂治疗骨关节炎的给药方案

Country Status (8)

Country Link
US (1) US20250082611A1 (https=)
EP (1) EP4373489A1 (https=)
JP (1) JP2024525897A (https=)
KR (1) KR20240038995A (https=)
CN (1) CN117693340A (https=)
CA (1) CA3224774A1 (https=)
IL (1) IL309085A (https=)
WO (1) WO2023002399A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
CN112654350A (zh) * 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment

Also Published As

Publication number Publication date
WO2023002399A1 (en) 2023-01-26
JP2024525897A (ja) 2024-07-12
KR20240038995A (ko) 2024-03-26
CA3224774A1 (en) 2023-01-26
EP4373489A1 (en) 2024-05-29
IL309085A (en) 2024-02-01
US20250082611A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
JP5478262B2 (ja) 抗癌剤
TWI389689B (zh) 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
KR102202481B1 (ko) 신규 용도
AU2016258198A1 (en) Compositions and methods of treating a neurodegenerative disease
CN117693340A (zh) Nlrp3抑制剂治疗骨关节炎的给药方案
IL272166B2 (en) A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(s3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-h7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment
WO1996003989A1 (en) Remedy for spinocerebellar degeneration
KR20120139721A (ko) 10-프로파길-10-데아자아미노프테린의 광학적으로 순수한 부분입체이성질체 및 이의 용도
EP0774257B1 (en) Use of piperazine and homopiperazine compounds for the inhibition of cellular adhesion and infiltration
US20240317740A1 (en) Novel compounds and their use
JP7591283B2 (ja) ブドウ膜黒色腫の治療のための併用療法
CN106459011B (zh) 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途
JP6173352B2 (ja) 筋萎縮性側索硬化症の治療方法
KR20210016103A (ko) Alk 단백질의 분해를 유도하는 신규 화합물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
ES2220133T3 (es) Composiciones de medicamentos que sirven para tratar las lesiones oseas en el mieloma multiple.
JP2024535799A (ja) Ｂｔｋ阻害剤及びｐｉ３キナーゼ阻害剤の組み合わせを使用したがん治療の方法
CN119816304A (zh) Nlrp3抑制剂的给药方案
JP2003513888A (ja) 神経疾患治療用医薬品
JP2007509883A (ja) 統合失調症の処置のためのａｍｐａ受容体アンタゴニストを含む組み合わせ
KR20200055117A (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP2005507901A5 (https=)
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
CN120154597A (zh) 银杏内酯a在治疗类风湿关节炎中的应用
CN121240859A (zh) 用于治疗健康状况的组合物和制备和使用小分子的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination